

GOG PARTNERS CONNECTION

A Quarterly Newsletter From GOG Partners, A GOG Foundation Program

INTENTIONAL PORTFOLIO MANAGEMENT: EMPOWERING GOG SITES TO DELIVER STRONGER OUTCOMES

The therapeutic landscape in gynecologic oncology is expanding at an unprecedented pace. Across all gynecologic cancers, including endometrial, cervical and ovarian cancers, the GOG Foundation, Inc. (GOG-F) and GOG Partners (GOG-P) clinical trial portfolio now includes a broad spectrum of trials: antibody–drug conjugates (ADCs), biomarker-selected therapies, and novel non-ADC targeted strategies. This diverse and enriched trial portfolio creates multiple pathways for sites to build comprehensive trial options and offer new therapies to patients.

Trial participation is central to our mission. Participation in clinical trials improves outcomes, and helps to advance the science in gynecologic oncology. Achieving success is a team effort, which requires a supportive culture, clear structure, and disciplined portfolio management.

As the therapeutic landscape grows more complex, partnership across the GOG-F and GOG-P network ensures that we can turn opportunity into access, and access into impact.

Strategic development of a comprehensive trial portfolio enhances overall success. Intentional portfolio management maximizes opportunities to have a potential practice changing trial for all patients who suffer from these gynecologic cancers. Purposeful planning not only expands a site's trial offerings, but also minimizes redundancy, efficient operations, and maximizes patient recruitment. Ultimately this planning and execution will catalyze an evolution in transforming the standard of care, leading to renewed hope for our patients and their families.

Endometrial Cancer: Matching Biology to Opportunity

The endometrial portfolio now spans adjuvant, first-line, and recurrent settings with both ADC, non-ADC and biomarker-selected approaches.

In the adjuvant space, HER2-directed therapy (e.g., GOG-3122/DESTINY-Endometrial02) addresses the approximately 20–30% of patients with HER2 over expression (2+/3+) who are at high risk for recurrence. While the first line management of dMMR tumors has been established in GOG-3031/RUBY, GOG-3041/DUO-E, and NRG-GY018, there remains an unmet need in the pMMR and IO naïve populations. The two distinct strategies in the first-line setting are maintenance designs which incorporate novel ADCs combined with immune checkpoint inhibitors after standard of care induction chemotherapy and immunotherapy and treatment trials seeking to replace the platin-based therapy with ADCs while at the same time introducing bispecific antibodies.

The recurrent/post-IO setting is particularly robust. Multiple ADC trials are ongoing, targeting FR α , B7H4, and HER2. Non-ADC strategies are directed at PI3K/AKT/PTEN alterations and histology-specific populations. Focused sequencing of trials —such as avoiding ADC-after-ADC and IO-after-IO exposure — require early planning and biomarker testing.

The message is clear: we have abundant clinical trial options to build a comprehensive portfolio that includes: 1 first-line trial, 2 recurrent ADC trials (one biomarker specific and one tumor agnostic) and 1-2 post ADC trials. Finally, early identification of potential patients and disciplined screening are essential to maximize patient access.



Brian Slomovitz, MD
Mount Sinai Medical Center
Uterine Portfolio Lead, GOG-P



David O'Malley, MD
The Ohio State University,
James Comprehensive Cancer Center
Ovarian Portfolio Lead, GOG-P



Ramez Eskander, MD
University of California San Diego
Moore's Cancer Center
Ovarian Portfolio Lead, GOG-P



Leslie Randall, MD
Inova Health
Cervical Portfolio Lead, GOG-P

Ovarian Cancer: Building a Structured Continuum

The ovarian cancer portfolio reflects a similarly dynamic environment.

Neoadjuvant and first-line maintenance strategies provide meaningful flexibility in portfolio construction. Sites can maintain neoadjuvant trials (e.g., GOG-3115/Mirvetuximab neoadjuvant; GOG-3068/HOTT) while preserving the option to enroll patients onto NRG-GY036 (12 vs 24 months of PARP inhibitor maintenance). If a patient does not enroll on one of the neoadjuvant platforms and is found to be HRD-negative, enrollment can shift to a biomarker-directed first-line maintenance strategy (e.g., GOG-3112/DESTINY-Ovarian01). If the patient is not biomarker positive, a biomarker-agnostic option remains available (e.g., GOG-3102/Trofuse-021). This structure allows each institution to maintain first-line maintenance options for both biomarker-selected and biomarker-unselected patient populations, ensuring that nearly every eligible patient has a clinical trial pathway.

In platinum-sensitive ovarian cancer (PSOC), treatment and maintenance trials coexist. For example, in patients progressing after PARPi, GOG-3133-S/FRAMework-01 is evaluating ADC versus a platinum doublet, while GOG-3126/FLORENZA allows all PSOC patients regardless of PARPi exposure. If not eligible for a treatment protocol, maintenance trials provide additional pathways (e.g., GOG-3103/Trofuse-022).

For platinum-resistant ovarian cancer (PROC), breadth is critical. We strongly encourage all of our sites to consider opening a biomarker-selected trial, as well as a non-biomarker selected study (examples of current ongoing trials are included):

- A biomarker-selected ADC option: GOG-3127/TREVI-OC-01, and more to come
- A biomarker-unselected ADC option: GOG-3096/REJOICE-Ovarian01, GOG-3132/BEHOLD-Ovarian01, and GOG-3133-R/FRAMework-01
- Non-ADC targeted strategies for specific molecular subsets: GOG-3066/DENALI, GOG-3129/MAESTRA-1, GOG-3137/MAESTRA-2, Combo-Match EAY191-N4, and Combo-Match EAY191-N5
- At least one biomarker-agnostic non-ADC study: GOG-3076/OnPrime, and GOG-3121/ULTIMUS-1

Attention to priorlines of therapy (3rd, 4th, or 5th line) can further expand eligibility. Early biomarker profiling and proactive navigation remain foundational.

Cervical Cancer: Maximizing Opportunities for Patients Requires Commitment to Keep the Momentum Going

We have all seen firsthand the highly positive impact that bevacizumab (GOG-240), immunotherapy (Keynote A18 and 826, GOG-3030/BEATcc, GOG-3016/EMPOWER cervical), and tisotumab vedotin (GOG-3023/InnovaTV 204, GOG-3024/InnovaTV 205, and GOG-3037) have all made for our cervical cancer patients. ALL of this was made possible by GOG sites, by those reading this newsletter and their patients. We are not finished, however; with still more improvements in treatment to be made.

Compared to ovarian and endometrial trials, the cervical cancer portfolio has fewer studies but requires as much effort because eligible patients are often met with barriers including social determinants of health, trial access, and disease related comorbidities. Managing these can be time consuming for PIs and staff, but with fewer opportunities available, we are the gatekeepers of trial access for cervical cancer patients. It's imperative that they be given opportunities to participate. Many of our trials have support services (e.g., transportation, childcare, etc.) to help address barriers to participation.

GOG-3101/Trofuse-020: Very high priority. Closing soon!

Phase 3, trop2-targeted ADC vs tisotumab vedotin or other MD choice chemotherapy, and the US/GOG PI is Dr. Ritu Salani. This trial is nearly completed, and it would be a big win to get this new treatment FDA-approved and into our clinics! The trial enrolls patients with any trop-2 expression, and the payload is a belotecan-derivative topoisomerase-1 inhibitor, which would bring this option to more patients than currently eligible for her2-directed ADC therapy.

GOG-3043/ROCC: This randomized trial of open vs robotic surgery for early-stage cervical cancer that allows sentinel node assessment and extrafascial hysterectomy for SHAPE trial candidates. Congratulations to PIs Dr. Kristin Bixel and Dr. Mario Leitao for being the second highest accruing study in the robust GOG Partners portfolio! We are currently at 406/840 patients enrolled which is in large part due to our highest accruing sites and the addition of our Canadian, Brazilian and KGOG colleagues. Let's keep the momentum going!

GOG-3116: This phase 4 study led by Dr. Scott Jordan will optimize and confirm the ocular safety of tisotumab vedotin. Eye exams are per the current FDA label with one monthly x 3 months after treatment is stopped to characterize any longer-term effects. Please consider referring your patients for this important trial!

GOG-3123/Trofuse-036: This trial can be considered a Keynote-826 or GOG-3030/BEATcc replacement that incorporates trop-2 ADC into Pembro +/- bevacizumab maintenance. This is a large global trial led by GOG with Dr. Brian Slomovitz serving as the US/GOG PI. The first 20 patients enrolled will receive study drug in a safety lead in. Subsequent patients will be randomized to Pembro +/- sac-TMT.

A Practical Framework for Sites

Given the growing menu of options, sites may consider a pragmatic portfolio model:

- At least one adjuvant study
- Two frontline options (one biomarker-selected, one biomarker-agnostic)
- 1–2 ADC trials in recurrent disease
- 1–2 non-ADC trials across different biomarkers or histologies

Programs that align portfolio structure with their patient population—and embed screening into routine workflow—are best positioned to succeed.

Call to Action

In order to be successful, programs should approach portfolio management with intention and discipline. For further information on how to best structure your portfolio, please contact Katie Campbell-Simms at kcampbell@gog.org.



Katie Campbell-Simms, BS
Executive Director, Clinical Trial Operations
The GOG Foundation, Inc.

CLINICAL TRIALS

The GOG-P Program is currently recruiting for 33 clinical trials

- 19 Ovary
- 5 Cervix
- 9 Endometrium

The GOG-P Program has 24 clinical trials under development:

- 18 Ovary
- 5 Cervix
- 1 Endometrium

To learn more about GOG-P Clinical Trials, please contact Katie Campbell at kcampbell@gog.org.

Search
Active Clinical Trials



Top 10 Principles for Portfolio Success



Embed clinical trials as a core institutional value



Make trial eligibility the first question in every care pathway



Implement proactive patient identification and pre-visit screening



Standardize research-focused clinic huddles



Actively balance the portfolio across lines of therapy



Anticipate trial closures and maintain a ready-to-open pipeline



Align faculty incentives with research engagement



Invest in education for patients, providers, and staff



Leverage data transparency and accountability



Build scale through institutional alignment and centralization.

SPECIAL RECOGNITION

Top 50 Accruing Sites - 3 Year

GOG Partners/NRG Combined Accrual

1	The James Gynecologic Oncology Mill Run/The Ohio State University	26	Western Pennsylvania Hospital/West Penn Hospital - Allegheny Health Network
2	University of Virginia	27	Levine Cancer Institute, Atrium Health (Carolinas Medical Center)
3	Women's Cancer Center of Nevada	28	University of Pennsylvania
4	University of Oklahoma Health Sciences Center, Stephenson Cancer Center	29	The Blavatnik Family - Chelsea Medical Center at Mount Sinai
5	Memorial Sloan Kettering Cancer Center	30	Winship Cancer Institute at Emory University
6	Women & Infants Hospital	21	Swedish Medical Center
7	Cleveland Clinic Foundation	32	Mount Sinai Medical Center
8	NYU Langone Health – Perlmutter Cancer Center	33	New Mexico Cancer Care Alliance/University of New Mexico Comprehensive Cancer Center
9	Georgia Cancer Center/Augusta University	34	University of Chicago Medical Center
10	University of Colorado Hospital - Anschutz Cancer Pavilion	35	University of Iowa Hospitals and Clinics
11	Froedtert and The Medical College of Wisconsin	36	Yale University
12	Duke University Medical Center	37	Oklahoma Cancer Specialists and Research Institute, LLC
13	Center of Hope	38	Huntsman Cancer Institute
14	Washington University School of Medicine	39	AdventHealth Orlando
15	Texas Oncology - Fort Worth (DFW) - USO	40	Virginia Commonwealth University (VCU) Massey Comprehensive Cancer Center
16	University of California San Diego Moores Cancer Center	41	University of Arkansas for Medical Sciences
17	HonorHealth Research and Innovation Institute	42	McGill University - MUHC
18	MD Anderson Cancer Center	43	Texas Oncology - Central/South - USO
19	University of Minnesota	44	SUNY Upstate Medical University
20	University of Rochester	45	Trials365, LLC
21	Rutgers Cancer Institute of NJ	46	UCLA Johnson Comprehensive Cancer Center
22	Northwestern University	47	University of Nebraska Medical Center
23	Indiana University Melvin and Bren Simon Comprehensive Cancer Center	48	University of Wisconsin
24	Abington Memorial Hospital - Asplundh Cancer Pavilion/Thomas Jefferson	49	University of Washington Fred Hutchinson Cancer Center (FHCC)/Seattle Cancer Care Alliance
25	Maine Medical Center	50	University of Alabama at Birmingham

Kathleen Moore, MD, Appointed Fred & Pamela Buffett Cancer Center’s Deputy Director

The Fred & Pamela Buffett Cancer Center has appointed Kathleen Moore, MD, as deputy director and director of Phase 1 oncology trials.

Dr. Moore is an internationally recognized leader in gynecologic oncology, known for her contributions to early-phase clinical trials and cancer research program development. In her role, Dr. Moore will provide strategic leadership across the cancer center as deputy director and will lead the Phase 1 Oncology Trials Program.

“My focus will be on expanding access to innovative early-phase studies, strengthening investigator-initiated and translational research, and accelerating the development of novel cancer therapeutics for patients,” Dr. Moore said.

[Click here](#) to read the full announcement.



Can glucocorticoid receptor activation inhibit apoptosis?

Revealing mechanisms of chemoresistance in ovarian cancer¹

Discover more

illuminate
PROC

©2025 Concept Therapeutics Incorporated. All rights reserved. DSE-01279 FEB 2025 ONC



Staying Connected: Communication Tools for GOG Investigators & Site Staff

The GOG-Foundation (GOG-F) and GOG Partners (GOG-P) recognize the importance of thoughtful and timely communication to provide our investigators and site staff with the information, resources, and education needed to be successful with the vast portfolio of trials. As an organization committed to keeping you informed, engaged, and supported as your trusted source of clinical trial information.

Here’s a quick guide to the GOG Communication Tools available to you:

GOG Quarterly Newsletter

The GOG Quarterly Newsletter is designed to keep our community informed and connected through a curated overview of the most important developments across the GOG portfolio. Each issue strives to deliver timely updates to include but not limited to: progress on clinical trials, mentions from the broader landscape, spotlights on individuals and teams through special recognition features, details on upcoming industry meetings, and highlight valuable educational opportunities. Together, these updates provide a comprehensive snapshot of the work, impact, and momentum driving the GOG mission forward.

Email Blasts

Email alerts are a critical tool for ensuring that investigators and site staff receive important information without delay. These messages may include:

- New protocol releases or revisions
- Study highlights and updates
- Safety updates and urgent notifications
- Meeting invitations and registration reminders
- Training requirements or platform updates
- Important Press Release Details

Social Media Channels

GOG’s social media platforms are a convenient way to stay connected with real-time news and broader community updates. Connect with us on the following social media channels:



GOG GYN-LIVE Podcast


The GOG GYN-LIVE Podcast brings listeners behind the scenes of the groundbreaking work shaping the future of cancer care across ovarian, uterine, cervical, vaginal, and vulvar malignancies.

Each episode features:

- Conversations with leading investigators and clinical experts
- Discussions on groundbreaking trial insights
- Real-world stories that illuminate the evolving landscape of gynecologic oncology



[Click here](#) to subscribe to the GOG GYN-LIVE Podcast feed or listen anywhere using the following podcasting apps.



GOG-F & FSGO ANNOUNCE NEW STRATEGIC PARTNERSHIP

The GOG Foundation, Inc. (GOG-F) and the Florida Society of Gynecologic Oncology (FSGO) are pleased to announce a new strategic partnership designating GOG as the educational provider for Industry Supported Symposia (ISS) beginning with the FSGO 32nd Annual Meeting in Longboat Key, Florida, June 11–14, 2026.



GOG-F and FSGO will collaborate to identify the most timely and meaningful symposium topics that will focus on the latest advances and clinical trial data in gynecologic oncology. The goal of this education is to improve patient outcomes, supporting high-quality, contemporary clinical practice. While ISS programs are separate from the official scientific agenda, they are designed to provide high-value clinical insights that clinicians can apply directly to patient care.

“The Florida Society of Gynecologic Oncology is thrilled to partner with the GOG to bring even more high-quality education to our 32nd Annual Meeting in Long Boat Key,” said Dr. Scott Jordan, FSGO 2026 Program Chair. “We are so excited to not just have many GOG-affiliated speakers participating in our program, but the addition of industry sponsored symposia will take our meeting’s educational goals to the next level.”

Dr. Thomas Herzog, GOG-F President said, “The GOG Foundation is thrilled to collaborate with FSGO and support the delivery of cutting-edge, practice-advancing education to the FSGO members and attendees. This partnership strengthens the mission-driven work of both organizations and reinforces our shared commitment to transforming the standard of gynecologic cancer care through innovation, research, and education.”

IN THE NEWS

GOG-3105/FERN-EC-01/DB-1303/BNT323 Press Release

On April 11, 2026: BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

[Click here](#) to read full BioNTech press release.

ROSELLA/GOG-3073/ENGOT-ov72 Press Release

On March 25, 2026: FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

[Click here](#) to read full Corcept Therapeutics press release.

KEYNOTE-B96/ENGOT-ov65 Press Release

On February 10, 2026: FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1)

[Click here](#) to read full FDA news release.

[Click here](#) to read full Merck press release.

ENDURING EDUCATION


Click the images below to access the enduring education materials.



GOG Highlight Reel

ENDURING EDUCATION MATERIALS AVAILABLE NOW

PRESENTED ON
Friday,
January 23, 2026



An Industry Supported Symposium at the IGCS 2025 Annual Global Meeting

Evidence Based Biomarker-Driven Advances in Ovarian & Endometrial Cancer: Equitable, Individualized and Accessible Care

This session is not included in the main event CME/CPD credit.

ENDURING EDUCATION AVAILABLE NOW

PRESENTED ON
Friday, November 7, 2025

GOG FOUNDATION® **GOG PARTNERS**



An Industry Supported Symposium at the IGCS 2025 Annual Global Meeting

FROM DATA TO DECISIONS: EVOLVING OPPORTUNITIES IN PLATINUM RESISTANT OVARIAN CANCER

This session is not included in the main event CME/CPD credit.

This educational activity is supported by an independent medical education grant from Carcept Therapeutics, Inc.

AVAILABLE NOW

ENDURING EDUCATION PRESENTED ON
FRIDAY, NOVEMBER 7, 2025

GOG FOUNDATION® **GOG PARTNERS**



An Industry Supported Symposium at the IGCS 2025 Annual Global Meeting


Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer

FIRST PRESENTATION
Decoding Endometrial Cancer: The Role of Molecular Profiling

AVAILABLE NOW

Alexander Olawaiye, MD
University of Pittsburgh Magee-Womens Hospital of UPMC Pittsburgh, Pennsylvania, USA

Eisai



An Industry Supported Symposium at the IGCS 2025 Annual Global Meeting

Global Perspective in Advanced, Recurrent Cervical Cancer: Resources, Opportunities and Access to Care

This session is not included in the main event CME/CPD credit.

PRESENTED ON
Thursday
November 6, 2025

AVAILABLE NOW

The GOG Foundation, Inc. is grateful for our commercial supporter for their unrestricted educational grant associated with this Symposium: GENMAB

Genmab



AN INDEPENDENT SATELLITE SYMPOSIUM DURING THE IGCS 2025 ANNUAL GLOBAL MEETING

Innovative horizons: Advancing platinum-resistant ovarian cancer (PROC) treatment with antibody-drug conjugates (ADCs)


To register for access today!

Be part of the conversation on the potential of ADCs to shape the future treatment landscape of PROC

CLICK HERE!

Prof. Kathleen Moore (Chair) USA
Prof. David O'Malley USA
Prof. Isabelle Ray-Coquard France

Daichi-Sankyo | **MSD**



PRESENTED ON
Wednesday,
November 5, 2025

An Industry Supported Symposium at the IGCS 2025 Annual Global Meeting

ENDURING EDUCATION AVAILABLE NOW!

THE LONG GAME IN ENDOMETRIAL CANCER: INTERPRETING PFS, OS, AND THE POWER OF BIOMARKERS

This session is not included in the main event CME/CPD credit.

GOG FOUNDATION® **GOG PARTNERS**



An Industry Supported Symposium at the IGCS 2025 Annual Global Meeting

Beyond the image: New opportunities in gynecologic cancer testing

This session is not included in the main event CME/CPD credit.

PRESENTED ON
Friday,
November 7, 2025

ENDURING EDUCATION AVAILABLE NOW!

This educational activity is supported by an independent medical education grant from Genentech

natera



An Industry Supported Symposium at the IGCS 2025 Annual Global Meeting

A NEW ERA IN RECURRENT LGSOC: INCORPORATING APPROVED THERAPIES, BIOMARKERS, AND CLINICAL STRATEGIES

This session is not included in the main event CME/CPD credit.

The GOG Foundation, Inc. is grateful for our commercial supporter for their unrestricted educational grant associated with this Symposium: Verastem

AVAILABLE NOW

PRESENTED ON
THURSDAY
NOVEMBER 6, 2025

This educational activity is supported by an independent medical education grant from Verastem

GOG FOUNDATION® **GOG PARTNERS**




Learn More About Endometrial and Ovarian Cancer

Visit GSK's Gynecologic Oncology YouTube Channel

[Click here to visit the channel](#)

For US Healthcare Professionals only

PSE-US-4980 | Mar 2026



UPCOMING INDUSTRY MEETINGS

2026 ASCO® ANNUAL MEETING

May 29-June 2, 2026 | Chicago, IL

[Click here](#) for more information.



31st Annual Meeting of the Florida Society of Gynecologic Oncology
The Resort at Long Boat Key Club, June 11-14, 2025

June 11-14, 2026 | Long Boat Key, FL

[Click here](#) for more information.

WAGO
Western Association of
Gynecologic Oncology

2026 ANNUAL MEETING

Wednesday,
June 17, 2026

Saturday,
June 20, 2026

Meritage Resort & Spa
Napa, California

June 17-20, 2026 | Napa, CA

[Click here](#) for more information.

2026 **ESMO GYNAECOLOGICAL CANCERS**
Annual Congress

COPENHAGEN DENMARK
17-19 JUNE 2026

June 17-19, 2026 | Copenhagen, Denmark

[Click here](#) for more information.

NRG Oncology 2026 Summer Semiannual Meeting

July 16-18 2026 | Denver, CO

[Click here](#) for more information.



July 17, 2026 | Denver, CO

Registration is anticipated to open mid-April.

IGCS 2026
Annual Global Meeting
MONTREAL
October 1 - 3

October 1-3, 2026 | Montreal, Canada

[Click here](#) for more information.

MADRID 2026 **ESMO** congress

MADRID SPAIN
23-27 OCTOBER 2026

October 23-27, 2026 | Madrid, Spain

[Click here](#) for more information.

2026 SGO ANNUAL MEETING RECAP

[Click here](#) to view the GOG Spotlight Interviews from the 2026 SGO Annual Meeting and make sure to check out the GOG Social Media channels on Facebook, Instagram, LinkedIn, and X for the GOG Trials that were presented at the meeting!

SGO ANNUAL MEETING ON WOMEN'S CANCER

ADVANCING SCIENCE
EMPOWERING TEAMS
EMBRACING CHANGE

SAN JUAN, PR • APRIL 10-13, 2026 • WWW.SGO.ORG

GOG 2026 INDUSTRY SPONSORS

The GOG-F and GOG-P would like to thank our Year-Round Sponsors for their support of our mission to transform the standard of care in gynecologic oncology.

PREMIER SPONSORS



PARNTER SPONSORS



SUPPORTING SPONSORS



The GOG is grateful for our Industry Collaboration Team Members

PLATINUM MEMBERS

abbvie

AstraZeneca

Daiichi-Sankyo

GOLD MEMBERS

Eisai, Inc.

Gilead | Kite